09 April 2019 : Hypothesis
Phytanoyl-CoA 2-Hydroxylase-Interacting Protein-Like Gene Is a Therapeutic Target Gene for Glioblastoma Multiforme
HuangDe Fu1ABCG, Bin Ge2ABCF, DuanKai Chen2BF, YueQing Wu3BF, QiSheng Luo1BF, XueYu Li1E, ChuanHua Zheng1E, QianLi Tang2DF*DOI: 10.12659/MSM.913895
Med Sci Monit 2019; 25:2583-2590
Abstract
Glioblastoma multiforme (GBM) is the most common primary CNS cancer and has a poor prognosis. This study searched for significant genes and the mechanisms involved in GBM. We used the Gene Expression Omnibus (GEO) to test the WHO normal and IV glioma database, used R tool to identify the significant gene, and finally, combined these with The Cancer Genome Atlas (TCGA) to verify the significant genes. Subsequently, we explored the biological mechanisms involved. Phytanoyl-CoA 2-hydroxylase-interacting protein-like gene (PHYHIPL) is downregulated in grade IV glioma (GBM). The downregulation of PHYHIPL in GBM is accompanied by poor overall survival in the TCGA database, which indicates that PHYHIPL is a protection gene in GBM development. Bioinformatics analysis shows that the poor prognosis with downregulated PHYHIPL may be the result of the TNF signaling pathway and the IL-17 signaling pathway, but good prognosis accompanied by upregulated PHYHIPL may be the result of retrograde endocannabinoid signaling and the cAMP signaling pathway. Protein-protein interactions (PPI) net indicated that PHYHIPL may play a vital role in cell metabolism, and we hypothesize that the downregulation mechanism may be the result of mutations of the β-catenin gene and the endogenous siRNA, as shown in previous studies. PHYHIPL may be a target gene for the treatment and prognosis of GBM.
Keywords: Metabolism, RNA, Small Interfering, Tumor Markers, Biological, Coenzyme A, Computational Biology, Databases, Genetic, Gene Regulatory Networks, Glioma, Intracellular Signaling Peptides and Proteins, Mutation, Nerve Tissue Proteins, Phytanic Acid
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
20 Mar 2024 : Clinical Research
Prevalence and Management of Chronic Pain, Including Neuropathic Pain, in Dialysis Patients with End-Stage ...Med Sci Monit In Press; DOI: 10.12659/MSM.943808
15 Mar 2024 : Clinical Research
Impact of Cluster Nursing Intervention on ICU Patients' Psychological Well-Being and Complications Associat...Med Sci Monit In Press; DOI: 10.12659/MSM.942855
26 Mar 2024 : Clinical Research
New Computerized Planning Algorithm and Clinical Testing of Optimized Nuss Bar Design for Patients with Pec...Med Sci Monit In Press; DOI: 10.12659/MSM.943705
07 May 2024 : Clinical Research
Treatment of AVN-Induced Proximal Pole Scaphoid Nonunion Using a Fifth and Fourth Extensor Compartmental Ar...Med Sci Monit In Press; DOI: 10.12659/MSM.944553
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952